NuCana plc Stock

NCNA

US67022C3043

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 14/11/2026 +04			5-day change	1st Jan Change
0.9326 ^USD	+0.28%		-0.53%	-74.09%

11-13	NuCana plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-12	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT

Analysts' recommendations: NuCana plc

15/10/24	Truist Slashes Price Target on NuCana to $20 From $150 Amid Discontinuation of NUC-3373, Keeps Buy Rating	MT
30/08/24	Top Midday Decliners	MT
30/08/24	William Blair Downgrades NuCana to Market Perform From Outperform	MT
21/11/22	Oppenheimer Trims NuCana's Price Target to $4 From $5, Maintains Outperform Rating	MT
22/09/22	Jefferies & Co. Adjusts NuCana's Price Target to $3 From $21, Keeps Buy Rating	MT

More recommendations

Managers and Directors: NuCana plc

Manager	Title	Age	Since
Hugh Griffith CEO	Chief Executive Officer	58	20/03/2008
Ian Webster DFI	Director of Finance/CFO	-	01/01/2019
Michelle Myers CTO	Chief Tech/Sci/R&D Officer	-	01/01/2022

Director	Title	Age	Since
Hugh Griffith BRD	Director/Board Member	58	20/03/2008
Andrew Kay CHM	Chairman	71	21/12/2020
Martin Mellish BRD	Director/Board Member	68	14/12/2009

More insiders

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/11/26	$0.9327	+0.28%	14,000
12/11/26	$0.9300	-1.04%	31,899
11/11/26	$0.9398	+0.51%	41,641
10/11/26	$0.9350	-2.67%	13,183
09/11/26	$0.9606	+2.44%	14,334

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - NuCana plc

Company calendar

Market Cap	3.04M 2.75M 2.55M 2.3M 4.33M 287M 4.48M 30.6M 12.14M 153M 11.41M 11.16M 486M	P/E 2024	-0.15x	P/E 2025	-0.2x
Enterprise Value	-20.54M -18.61M -17.21M -15.53M -29.27M -1.94B -30.3M -207M -81.99M -1.03B -77.06M -75.43M -3.28B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99%	Yield 2024 *	-	Yield 2025	-

11-13	NuCana plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-12	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
11-11	European Equities Traded in the US as ADRs Tick Higher in Wednesday Trading	MT
11-05	European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading	MT
11-03	European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading	MT
10-28	European Equities Traded in the US as American Depositary Receipts Steady in Wednesday Trading	MT
10-26	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
10-23	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
10-20	European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading	MT
10-15	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
10-07	European Equities Traded in US as ADRs Fall in Wednesday Trading	MT
10-01	European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading	MT
09-30	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT

09-30	NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe	AQ
08-14	NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
06-01	NuCana Appoints Ian Webster as Chief Financial Officer	AQ
05-15	NuCana Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05-06	NuCana : Notice of AGM - 2026	PU

1 day	+0.28%
1 week	-0.53%
Current month	-7.65%
1 month	-11.17%
3 months	-36.98%
6 months	-50.12%
Current year	-74.09%

1 week	0.88	1
1 month	0.88	1.17
Current year	0.88	3.81
1 year	0.88	4.55
3 years	0.88	3,882
5 years	0.88	16,598.5
10 years	0.88	160,000

NuCana plc Stock

Stocks

NCNA

US67022C3043

Biotechnology & Medical Research

Valuation: NuCana plc

Chart: NuCana plc

Latest news: NuCana plc

Analysts' recommendations: NuCana plc

Press Releases: NuCana plc

Quotes and Performance

Price Extremes

Managers and Directors: NuCana plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/04/26	Theresa Bruce	Free	Chief Operating Officer	132,600,130	-
18/03/26	David Harrison	Other	Head of Translational Medicine	283,984,182	-
18/03/26	Hugh Griffith	Other	Founder	4,352,841,381	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUCANA PLC	+0.28%	-0.53%	-	-	4.02M
Average	+0.28%
Weighted average by Cap.	+0.28%

	2024	2025
Net sales	-	-
Net income	-19M -17.22M -15.92M -14.37M -27.07M -1.79B -28.03M -191M -75.85M -957M -71.29M -69.78M -3.04B	-29.35M -26.6M -24.6M -22.2M -41.83M -2.77B -43.31M -296M -117M -1.48B -110M -108M -4.69B
Net Debt	-6.56M -5.94M -5.5M -4.96M -9.35M -618M -9.68M -66.04M -26.19M -330M -24.61M -24.09M -1.05B	-23.58M -21.36M -19.76M -17.83M -33.6M -2.22B -34.78M -237M -94.12M -1.19B -88.47M -86.59M -3.77B

Markets		Quality
Nasdaq	NCNA	Delayed
CBOE	NCNA	Real-time